trending Market Intelligence /marketintelligence/en/news-insights/trending/_WGZKeKZ6L_b45EKzPAUHA2 content esgSubNav
In This List

Blueprint Medicines closes common stock offering

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Blueprint Medicines closes common stock offering

Blueprint Medicines Corp. closed its underwritten public offering of 5,750,000 common shares priced at $40 apiece with estimated net proceeds of about $215.6 million.

The underwriters for the offering fully exercised their option to buy additional common shares.

Goldman Sachs & Co., Morgan Stanley and Cowen and Co. acted as joint book-running managers for the offering, with Raymond James serving as co-manager.